サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654295

破傷風トキソイドワクチンの市場規模、シェア、動向分析レポート：ワクチン別、疾患別、最終用途別、地域別、セグメント予測、2025年～2030年

Tetanus Toxoid Vaccine Market Size, Share & Trends Analysis Report By Vaccine (Diphtheria, Tetanus, And Pertussis (DTaP)), By Disease (Tetanus, Diphtheria), By End Use (Hospital, Specialty Clinics), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 153 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.66円
破傷風トキソイドワクチンの市場規模、シェア、動向分析レポート：ワクチン別、疾患別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年01月21日
発行: Grand View Research
ページ情報: 英文 153 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

破傷風トキソイドワクチン市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、破傷風トキソイドワクチンの世界市場規模は2030年までに80億9,000万米ドルに達すると予測され、2025年から2030年までのCAGRは5.67％で拡大する見込みです。

破傷風トキソイドワクチン産業は、予防接種プログラムへの注目の高まりとワクチンで予防可能な病気に対する意識の高まりにより、著しい成長を遂げています。破傷風は神経系に影響を及ぼす重篤な細菌感染症であり、特にワクチン接種率が低い地域では、依然として世界の健康懸念となっています。ワクチン接種の普及拡大やヘルスケアインフラの整備は、市場拡大を後押しする主要因です。

市場成長に大きく寄与しているのは、複数の疾病に対する幅広い予防効果を提供する混合ワクチンの利用可能性です。ジフテリア・破傷風・百日咳（DTaP）ワクチンは、小児科の予防接種スケジュールで広く接種されており、これらの重篤な感染症に対する早期の防御を保証しています。同様に、ジフテリア・破傷風（DT）ワクチンは、百日咳の予防接種を受けることができない人々にとって不可欠であり、代替予防接種の選択肢を支えています。さらに、破傷風・ジフテリア・百日咳（Tdap）ワクチンは、青少年や成人のブースター接種において重要な役割を果たし、長期的な免疫力を強化し、疾病の伝播を減少させます。

この市場は、対象疾患によるワクチンの分類によってさらに強化されています。破傷風に焦点を当てたワクチンは依然として予防接種戦略の中心ですが、ジフテリア予防を統合することで全体的な効果が高まる。特定の患者グループ向けに調整された他のワクチン製剤が含まれることで、より包括的な予防接種アプローチが可能になり、多様な集団へのアクセスが拡大します。

ワクチンの普及には、流通チャネルが極めて重要な役割を果たします。病院は一次予防接種センターとして、特に緊急の創傷管理ケースにおいて破傷風トキソイドワクチンにすぐにアクセスできるようにしています。専門クリニックは、特に妊婦や旅行者などのハイリスクグループに定期的な予防接種を提供することで、大きな貢献をしています。さらに、地域医療センターや薬局を含むその他のヘルスケアプロバイダーも、ワクチン接種サービスにおける役割を拡大し、市場への浸透を高めています。

ワクチン製剤の絶え間ない進歩や、予防接種率向上のための政府による取り組みの増加により、市場は今後数年間で安定した成長を遂げる見通しです。

破傷風トキソイドワクチン市場レポート・ハイライト

  • 2024年の破傷風トキソイドワクチン業界では、ジフテリア・破傷風・百日咳（DTaP）がワクチンセグメントの最大シェアを占めました。この優位性は、定期予防接種プログラムにおいてDTaPが広く採用され、特に小児やブースターワクチン接種スケジュールにおいて、複数の細菌感染に対する包括的な防御を提供していることに起因しています。
  • 疾患別では、破傷風が2024年の市場成長への支配的な貢献者であり続けました。破傷風に関連する合併症の発生率が高いこと、特にワクチン未接種の集団や新生児や外傷患者などのハイリスクグループにおいて、効果的なワクチン接種戦略の需要が高まっており、破傷風トキソイド予防接種の重要性が高まっています。
  • 最終用途セグメントでは、病院が2024年の市場を独占しました。病院は、ワクチン接種プログラム、緊急予防、暴露後の破傷風管理において重要な役割を果たしており、特に怪我や創傷の治療においてタイムリーなワクチン投与を保証しています。訓練を受けたヘルスケア専門家がいることが、病院を拠点とした予防接種の効率性をさらに支えています。
  • 北米は、先進的なヘルスケア・インフラ、確立された予防接種プログラム、ワクチンで予防可能な病気に対する意識の高まりなどを背景に、2024年の市場をリードしました。定期予防接種と補助接種を促進する政府の好意的な政策やイニシアティブが、この地域の市場優位性をさらに高めています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 破傷風トキソイドワクチン市場の変数、動向、範囲

  • 親市場の見通し
  • 補助市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 破傷風トキソイドワクチン分析ツール
    • ポーターの分析
    • PESTEL分析

第4章 破傷風トキソイドワクチン市場：ワクチンの推定・動向分析

  • 破傷風トキソイドワクチン市場：ワクチンセグメントのダッシュボード
  • 破傷風トキソイドワクチン市場：ワクチンの変動分析、2024年および2030年
  • ジフテリア・破傷風・百日咳（DTaP）
  • ジフテリアと破傷風（DT）
  • 破傷風・ジフテリア・百日咳（Tdap）

第5章 破傷風トキソイドワクチン市場：疾患の推定・動向分析

  • 破傷風トキソイドワクチン市場：疾患セグメントのダッシュボード
  • 破傷風トキソイドワクチン市場：疾患の変動分析、2024年および2030年
  • 破傷風
  • ジフテリア
  • その他

第6章 破傷風トキソイドワクチン市場：最終用途の推定・動向分析

  • 破傷風トキソイドワクチン市場：最終用途セグメントのダッシュボード
  • 破傷風トキソイドワクチン市場：最終用途の変動分析、2024年および2030年
  • 病院
  • 専門クリニック
  • その他

第7章 破傷風トキソイドワクチン市場：地域の推定・動向分析

  • 破傷風トキソイドワクチン市場シェア、地域別、2024年および2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • ノルウェー
    • スウェーデン
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東およびアフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート
    • 南アフリカ

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業分類
  • 企業ヒートマップ分析
  • 企業プロファイル
    • Pfizer, Inc.
    • GSK plc.
    • Sanofi
    • Merck &Co., Inc.
    • Grifols, SA
    • Emergent BioSolutions Inc.
    • Virbac
    • Zoetis Services LLC
    • Ceva.
    • Abbott
図表

List of Tables:

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 4 Global Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 5 Global Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 8 North America Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 9 North America Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 U.S. Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 11 U.S. Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 12 U.S. Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Canada Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 14 Canada Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 15 Canada Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 Mexico Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 17 Mexico Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 18 Mexico Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 19 Europe Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 21 Europe Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 22 Europe Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 Germany Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 24 Germany Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 25 Germany Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 U.K. Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 27 U.K. Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 28 U.K. Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 France Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 30 France Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 31 France Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Italy Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 33 Italy Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 34 Italy Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Spain Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 36 Spain Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 37 Spain Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Denmark Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 39 Denmark Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 40 Denmark Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Sweden Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 42 Sweden Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 43 Sweden Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 44 Norway Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 45 Norway Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 46 Norway Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 China Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 52 China Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 53 China Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Japan Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 55 Japan Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 56 Japan Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 India Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 58 India Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 59 India Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 60 South Korea Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 61 South Korea Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 62 South Korea Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 Australia Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 64 Australia Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 65 Australia Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Thailand Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 67 Thailand Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 68 Thailand Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 69 Latin America Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 71 Latin America Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 72 Latin America Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 73 Brazil Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 74 Brazil Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 75 Brazil Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 76 Argentina Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 77 Argentina Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 78 Argentina Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 83 South Africa Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 84 South Africa Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 85 South Africa Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 89 UAE Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 90 UAE Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 91 UAE Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Tetanus toxoid vaccine market segmentation
  • Fig. 8 Market snapshot, 2024
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Market challenge relevance analysis (current & future impact)
  • Fig. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Tetanus toxoid vaccine market: Vaccine movement analysis
  • Fig. 16 Tetanus toxoid vaccine market: Vaccine outlook and key takeaways
  • Fig. 17 Diphtheria, tetanus, and pertussis (DTaP) tetanus toxoid vaccine market estimates and forecasts, 2018 - 2030
  • Fig. 18 Diphtheria and tetanus (DT) tetanus toxoid vaccine market estimates and forecasts, 2018 - 2030
  • Fig. 19 Tetanus, diphtheria and pertussis (Tdap) tetanus toxoid vaccine market estimates and forecasts, 2018 - 2030
  • Fig. 20 Tetanus, Diphtheria and Pertussis (Tdap) tetanus toxoid vaccine market estimates and forecasts, 2018 - 2030
  • Fig. 21 Tetanus toxoid vaccine market: Disease movement analysis
  • Fig. 22 Tetanus toxoid vaccine market: Disease outlook and key takeaways
  • Fig. 23 Tetanus market estimates and forecasts, 2018 - 2030
  • Fig. 24 Diphtheria market estimates and forecasts, 2018 - 2030
  • Fig. 25 Others market estimates and forecasts, 2018 - 2030
  • Fig. 26 Tetanus toxoid vaccine market: End use movement analysis
  • Fig. 27 Tetanus toxoid vaccine market: End use outlook and key takeaways
  • Fig. 28 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 29 Specialty clinics market estimates and forecasts, 2018 - 2030
  • Fig. 30 Others market estimates and forecasts, 2018 - 2030
  • Fig. 31 Regional Marketplace: Key Takeaways
  • Fig. 32 Regional Outlook, 2024 & 2030
  • Fig. 33 Global tetanus toxoid vaccine market, Region Movement Analysis
  • Fig. 34 North America tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 40 U.K. tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 41 France tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 49 China tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 50 India tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 60 UAE tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-502-4

Tetanus Toxoid Vaccine Market Growth & Trends:

The global tetanus toxoid vaccine market size is anticipated to reach USD 8.09 billion by 2030 and is expected to expand at a CAGR of 5.67% from 2025 to 2030, according to a new report by Grand View Research, Inc. The tetanus toxoid vaccine industry is witnessing significant growth due to the increasing focus on immunization programs and rising awareness about vaccine-preventable diseases. Tetanus, a severe bacterial infection affecting the nervous system, remains a global health concern, particularly in regions with low vaccination coverage. The expanding adoption of vaccination drives and improved healthcare infrastructure are key factors propelling market expansion.

A major contributor to market growth is the availability of combination vaccines, which provide broader protection against multiple diseases. The Diphtheria, Tetanus, and Pertussis (DTaP) vaccine is widely administered in pediatric immunization schedules, ensuring early protection against these serious infections. Similarly, the Diphtheria and Tetanus (DT) vaccine is essential for individuals who cannot receive the pertussis component, supporting alternative immunization options. Additionally, the Tetanus, Diphtheria, and Pertussis (Tdap) vaccine plays a crucial role in booster doses for adolescents and adults, reinforcing long-term immunity and reducing disease transmission.

The market is further strengthened by the classification of vaccines based on target diseases. While Tetanus-focused vaccines remain central to immunization strategies, the integration of Diphtheria protection enhances overall effectiveness. The inclusion of other vaccine formulations tailored for specific patient groups contributes to a more comprehensive immunization approach, expanding accessibility across diverse populations.

Distribution channels play a pivotal role in ensuring widespread vaccine availability. Hospitals serve as primary immunization centers, offering immediate access to tetanus toxoid vaccines, especially in emergency wound management cases. Specialty clinics contribute significantly by providing routine vaccinations, particularly for high-risk groups such as pregnant women and travelers. Additionally, other healthcare providers, including community health centers and pharmacies, are expanding their role in vaccination services, enhancing market penetration.

With continuous advancements in vaccine formulations and increasing governmental efforts to improve immunization rates, the market is poised for steady growth in the coming years.

Tetanus Toxoid Vaccine Market Report Highlights:

  • The vaccine segment of Diphtheria, Tetanus, and Pertussis (DTaP) held the largest share of the tetanus toxoid vaccine industry in 2024. This dominance can be attributed to the widespread adoption of DTaP in routine immunization programs, offering comprehensive protection against multiple bacterial infections, particularly in pediatric and booster vaccination schedules.
  • In the disease segment, tetanus remained the dominant contributor to market growth in 2024. The high incidence of tetanus-related complications, particularly in unvaccinated populations and high-risk groups such as newborns and trauma patients, has driven demand for effective vaccination strategies, reinforcing the importance of tetanus toxoid immunization.
  • In end-use segment, hospitals dominated the market in 2024. Hospitals play a crucial role in vaccination programs, emergency prophylaxis, and post-exposure tetanus management, ensuring timely administration of vaccines, especially in cases of injuries and wound care. The availability of trained healthcare professionals further supports the efficiency of hospital-based immunization.
  • North America led the market in 2024, driven by advanced healthcare infrastructure, well-established immunization programs, and increasing awareness about vaccine-preventable diseases. Favorable government policies and initiatives promoting routine and booster vaccinations have further contributed to regional market dominance.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Tetanus Toxoid Vaccine Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Increasing government immunization programs
      • 3.3.1.2. Rising awareness & preventive healthcare
      • 3.3.1.3. Increasing birth rates & pediatric vaccination
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Vaccine shortages & supply chain issues
      • 3.3.2.2. Low awareness in developing regions
  • 3.4. Tetanus Toxoid Vaccine Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Tetanus Toxoid Vaccine Market: By Vaccine Estimates & Trend Analysis

  • 4.1. Tetanus Toxoid Vaccine Market: Vaccine Segment Dashboard
  • 4.2. Tetanus Toxoid Vaccine Market: By Vaccine Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Diphtheria, Tetanus, and Pertussis (DTaP)
    • 4.3.1. Diphtheria, Tetanus, and Pertussis (DTaP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Diphtheria and Tetanus (DT)
    • 4.4.1. Diphtheria and Tetanus (DT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Tetanus, Diphtheria and Pertussis (Tdap)
    • 4.5.1. Tetanus, Diphtheria and Pertussis (Tdap) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Tetanus Toxoid Vaccine Market: Disease Estimates & Trend Analysis

  • 5.1. Tetanus Toxoid Vaccine Market: Disease Segment Dashboard
  • 5.2. Tetanus Toxoid Vaccine Market: By Disease Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Tetanus
    • 5.3.1. Tetanus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Diphtheria
    • 5.4.1. Diphtheria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Tetanus Toxoid Vaccine Market: End Use Estimates & Trend Analysis

  • 6.1. Tetanus Toxoid Vaccine Market: End Use Segment Dashboard
  • 6.2. Tetanus Toxoid Vaccine Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Specialty Clinics
    • 6.4.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Tetanus Toxoid Vaccine Market: Regional Estimates & Trend Analysis

  • 7.1. Tetanus Toxoid Vaccine Market Share, By Region, 2024 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018- 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Norway Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Sweden
      • 7.3.9.1. Sweden Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Kuwait
      • 7.6.4.1. Kuwait Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. South Africa Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Pfizer, Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. GSK plc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Sanofi
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Merck & Co., Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Grifols, S.A.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Emergent BioSolutions Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Virbac
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Zoetis Services LLC
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Ceva.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Abbott
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives